At the 61st ASH Annual Meeting & Exposition, James Ferrara, Icahn School of Medicine at Mount Sinai, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!
Questions
1. What are the most important unmet needs in the treatment of patients with graft-versus-host disease (GvHD)? (0:05)
2. What have been the most important recent advances in pretreatment and posttreatment prophylaxis of GvHD? (1:14)
3. What progress has been made in the identification of biomarkers that might predict the risk of GvHD? (2:10)
4. Could you give us a brief overview of the most promising emerging approaches in the treatment of GvHD? (3:08)
5. What factors should be considered when selecting the most appropriate treatment for an individual? (4:32)
James Ferrara is IP for biomarkers of acute GVHD, licensed to VIRACOR
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
